-
ASCO GU 2025 | Dr. Xuefeng Qiu and Dr. Darren Poon：Advancing Precision Medicine in Prostate Cancer
The 2025 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2025) has already taken place in San Francisco, USA. This globally renowned academic event brought together top oncology scholars to jointly explore the cutting-edge breakthroughs and future directions in the field of genitourinary oncology.In this insightful exchange, Dr. Xuefeng Qiu from…
-
ASCO GU 2025 | Professors Jun Guo, Xinan Sheng, and Bixia Tang: Chinese Innovative Drugs Enter the Global Stage, Expanding the Benefits in Urothelial
With the rapid advancement of ADC-based combination immunotherapies globally, the treatment landscape for advanced urothelial carcinoma has undergone a dramatic transformation, leading to multiple updates in clinical guidelines. This year’s ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13–15 in San Francisco, where Professor Jun Guo from Peking University Cancer Hospital led a…
-
New Insights from the MARGOT/TBCRC052 Trial on HER2+ Breast Cancer Treatment
The MARGOT/TBCRC052 trial, presented at SABCS 2024, explored the efficacy of margetuximab + paclitaxel + pertuzumab (TMP) versus the standard trastuzumab + paclitaxel + pertuzumab (THP) in HER2+ stage II-III…
-
Throwback to #SABCS24: Key Insights from the ZEST Trial
Prof. Nicholas Turner and colleagues presented findings from ZEST, the first Phase 3 trial evaluating MRD-guided therapy in breast cancer using circulating tumor DNA (ctDNA) surveillance.
-
New Insights on Tamoxifen Use After Breast Conservation Surgery for DCIS!
At SABCS, Jean Wright presented a new analysis from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trials, providing critical insights into the role of tamoxifen for patients with “good risk”…
-
Advancing Precision Medicine in Prostate Cancer: Expert Insights from Professor Qiu Xuefeng & Dr. Darren Poon
How are PARP inhibitors, ARPIs, and radioligand therapy reshaping the treatment landscape for mCRPC? In this exclusive conversation, Professor Qiu Xuefeng and Dr. Darren Poon dive into the latest advancements in precision oncology, discussing key challenges, emerging therapies, and the impact of HRR and BRCA testing on treatment decisions.
-
Throwback to #SABCS24: Final Survival Results from the ADAPT HR+/HER2- Trial
Prof. Sherko Kuemmel and the WSG Study Group presented key findings from the ADAPT HR+/HER2- chemotherapy trial, refining treatment strategies for high-risk HR+/HER2- early breast cancer.
-
WCLC 2024 | Selected Oral Presentations: Novel Immunotherapy Strategies and Combination Therapies
The 2024 World Conference on Lung Cancer is happening in San Diego from September 7th to 10th! The WCLC website has already released some groundbreaking abstracts. Here are the key…
Connecting Medical Expertise through Media